EMERGO EUROPE

24 March 2009

Mr. Jeff Wang
LumiQuick Diagnostics, Inc.
2946 Scott Blvd.
Santa Clara, CA 95054

Dear Mr.Jeff Wang:

I am writing to inform you that today, we have notified by registered mail the Competent Authority in the following countries:

Austria	Bulgaria	Cyprus	Czech Republic	Denmark	Estonia
Finland	France	Germany	Greece	Hungary	Iceland
Ireland	Italy	Latvia	Liechtenstein	Lithuania	Luxembourg
Malta	The Netherlands		Norway	Poland	Portugal
Romania	Slovakia	Slovenia	Spain	Sweden	Switzerland
United Kingdom					

With this notification, LumiQuick Diagnostics, Inc. has met the requirements of the In-vitro Diagnostics Directive, 98/79/EC for the following devices:

- Adeno/Rota Virus
- Cardiac Marker
- Dengue IgG/IgM Combo (registered only in Italy and The Netherlands)
- Drugs of Abuse
- Fecal Occult Blood (registered only in Italy and The Netherlands)
- H. Pylori Ab/Ag
- HCG
- Legionella (registered only in Italy and The Netherlands)
- LH (registered only in Italy and The Netherlands)
- Strep A (registered only in Italy and The Netherlands)

As of today and without any further notice from the respective Competent Authorities, LumiQuick Diagnostics, Inc. can consider the respective devices and Authorized Representative as officially registered.

If you have any questions, please do not hesitate to contact me.

Yours sincerely,

Rene van de Zande
President & CEO
Emergo Europe

Digitally signed by Monastîrschii Viorica
Date: 2021.01.22 11:37:41 EET
Reason: MoldSign Signature
Location: Moldova

Emergo Europe Molenstraat 15, 2513 BH The Hague, The Netherlands Telephone: +31.70.345.8570 Fax: +31.70.346.7299